AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
Executive Summary
AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO
You may also be interested in...
License To Fill: Pipeline Top AstraZeneca Priority Under Brennan
AstraZeneca's plans to bolster its product pipeline include further efforts to tap external technology sources, according to CEO David Brennan
License To Fill: Pipeline Top AstraZeneca Priority Under Brennan
AstraZeneca's plans to bolster its product pipeline include further efforts to tap external technology sources, according to CEO David Brennan
AstraZeneca U.S. succession plan
AstraZeneca Senior VP-U.S. Commercial Operations Tony Zook will replace U.S. President and Exec VP-North America David Brennan effective Jan. 1. Brennan has been named to succeed retiring CEO Tom McKillop (1"The Pink Sheet" Aug. 1, 2005, p. 11). Zook, who joined predecessor company Astra in 1997, previously served as AstraZeneca VP-sales; he has been leading U.S. commercial operations since Brennan was promoted to North America head in 2001 (2"The Pink Sheet" June 4, 2001, p. 32)...